Semaglutide Improves Daily Life for Patients with Diabetes and Kidney Disease
司美格魯肽改善糖尿病與腎臟病患者的日常生活
更新於: 2026年6月4日 下午01:20
For adults managing both type 2 diabetes and chronic kidney disease, life can often feel like a constant struggle with health limitations.
對於同時患有第二型糖尿病與慢性腎臟病的成年人來說，生活往往像是與健康局限搏鬥的長期抗爭。
However, exciting new data from the landmark FLOW trial brings a message of hope.
然而，來自里程碑式「FLOW試驗」令人振奮的新數據帶來了希望。
Presented at the 63rd ERA Congress, the study revealed that once-weekly semaglutide does more than just protect kidney function; it significantly enhances a patient's overall quality of life.
該研究在第63屆歐洲腎臟協會(ERA)大會上發表，結果顯示，每週一次的司美格魯肽(Semaglutide)不僅能保護腎功能，還能顯著提升患者的整體生活品質。
Results showed that while patients on a placebo saw their health utility scores decline over two years, those treated with semaglutide maintained stability.
結果顯示，安慰劑組患者在兩年內的健康效用評分下降，而接受司美格魯肽治療的患者則保持穩定。
Patients reported improvements in mobility, self-care, and pain management.
患者回報在行動力、自我照護與疼痛管理方面均有所改善。
Despite initial concerns that gastrointestinal side effects might hinder these gains, the study confirms that the benefits to physical functioning far outweigh these issues.
儘管最初擔憂胃腸道副作用可能會阻礙這些成效，但研究證實，生理功能方面的益處遠遠超過這些問題。
For both doctors and patients, this evidence highlights that treatment goals should include not just longevity, but the actual quality of daily life, proving semaglutide is a vital tool for those navigating these complex conditions.
對於醫師與患者而言，這項證據強調了治療目標不僅應包含延長壽命，還應重視實際的日常生活品質，證明司美格魯肽是患者面對這些複雜病症時至關重要的工具。
